Navigation Links
Ardea Biosciences Reports Recent Accomplishments and Second Quarter 2011 Financial Results
Date:8/5/2011

 We have completed Phase 2b clinical studies of lesinurad and continue to advance the drug in longer term extensions in preparation for Phase 3 development.  Our next-generation URAT1 inhibitor, RDEA3170, is currently in preclinical development. BAY 86-9766 (RDEA119) is a potent and specific inhibitor of mitogen-activated ERK kinase (MEK) for the treatment of cancer being developed under a global license agreement with Bayer HealthCare. BAY 86-9766 (RDEA119) is currently in a Phase 2 study in patients with hepatocellular carcinoma in combination with sorafenib and a Phase 1/Phase 2 study in patients with advanced pancreatic cancer in combination with gemcitabine.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Such statements include, but are not limited to, statements regarding our plans and goals, the expected properties and benefits of lesinurad (RDEA594), BAY 86-9766 (RDEA119) and our other compounds and the timing and results of our preclinical, clinical and other studies.  Risks that contribute to the uncertain nature of the forward-looking statements include risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, costs associated with our drug discovery and development programs, and risks related to the outcome of our business development activities, including collaboration or license agreements.  These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the head
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Ardea Biosciences to Present at Upcoming Investor Conferences
2. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
3. Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results
4. Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
5. Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering
6. Ardea Biosciences Prices Public Offering of Common Stock
7. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
8. Ardea Biosciences to Present at Two Upcoming Investor Conferences
9. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
10. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
11. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 Terascala, the industry leader ... Alan Swahn, a former vice president of product management ... vice president of marketing. Terascala’s software when combined with ... create the highest performance and most reliable solutions for ... guide Terascala’s channel expansion and broaden its product portfolio. ...
(Date:7/10/2014)... July 10, 2014 Senior supply chain ... professional associations, addressed the challenges of “Reducing Cost, Lead ... Industries” through strategic sourcing. Describing the partnership of the ... Supply Chain Management Institute ( SCMI) of the ... June 24 at the Kroc Institute of Peace and ...
(Date:7/10/2014)... 10, 2014 Research and Markets ( ... "International Photonic Integrated Circuit (Monolithic Integration, Hybrid ... report to their offering. ... of photonic integration traces its roots in the ... of photonic integration went unexplored and unfulfilled for ...
(Date:7/10/2014)... the journal PNAS (Proceedings of the National Academy ... and sleep deprivation have a significant effect on our ... the best time of day to test for diseases ... medicines effectively. , Researchers from the University of Surrey ... links between sleep deprivation, body clock disruption and metabolism, ...
Breaking Biology Technology:Terascala Expands Executive Team 2Terascala Expands Executive Team 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Time of day crucial to accurately test for diseases, new research finds 2
... Genetics, Inc., (Pinksheets: VRAL) and its President, Haig Keledjian, ... with Timothy and Thomas LLC ("T&T") and its principals ... Settlement ends the almost 5-year-old lawsuit between the parties ... the Northern District of Illinois, originally initiated in March ...
... ANNAPOLIS, Md., Jan. 28, 2011 Anyone curious about ... plasma contributes to lifesaving medicines can now learn about ... Plasma Protein Therapeutics Association (PPTA). "Becoming a Plasma Donor," ... a committed plasma donor at one of the 400-plus ...
... This release is available in Spanish and ... observed for eons. From this fibrous diet consisting mainly of ... substances of no nutritional value to most animals, ruminants manage to ... keepers. And now, the cow, or rather the network ...
Cached Biology Technology:Viral Genetics Settles Litigation and Reacquires African Rights for HIV/AIDS Products 2Viral Genetics Settles Litigation and Reacquires African Rights for HIV/AIDS Products 3New Video on Plasma Donation Available 2How now, inside the cow: Nearly 30,000 novel enzymes for biofuel production improvements 2How now, inside the cow: Nearly 30,000 novel enzymes for biofuel production improvements 3How now, inside the cow: Nearly 30,000 novel enzymes for biofuel production improvements 4How now, inside the cow: Nearly 30,000 novel enzymes for biofuel production improvements 5
(Date:7/10/2014)... or even improve the state of fisheries resources ... the Mediterranean has deteriorated over the past 20 ... species reported in the Cell Press journal ... for stringent monitoring of Mediterranean fishing activities, better ... in Mediterranean waters. , Their data show that ...
(Date:7/10/2014)... for Interdisciplinary Research (MIIR) and the Marshall University ... they will be partnering with an international biosciences ... the agreement with Shanghai-based HD Biosciences Co. Ltd., ... risks of discovery and development of these new ... property and commercialization rights to products developed through ...
(Date:7/10/2014)... incubator, received a $1.4 million federal grant to develop ... bleeding during brain surgery. , Surgeons can spray the ... solutions in the gel will cohere and control bleeding ... gel can shorten an intracranial surgery by 30- 45 ... patient,s skull to be open and less anesthesia, reducing ...
Breaking Biology News(10 mins):Mediterranean fish stocks show steady decline 2Marshall University to partner with international company in drug development venture 2A start-up at NJIT develops bleeding-control gel for brain surgery 2
... common drugs for advanced ovarian cancer: paclitaxel, cyclophosphamide, and topotecan. ... a patient is likely to respond. And, unfortunately, picking the ... this month,s issue of the journal PLoS ONE , ... study used a sophisticated model of ovarian cancer genetics to ...
... Mass. A Navy-sponsored project to design a biologically inspired, swimming ... common bending rules for the tips of wings, fins, flukes, ... animal species. The study, led by John H. ... in Woods Hole, where he is a visiting scientist, is ...
... , , , , ... , AUDIO: Falon Tilley and ... Click here for more information. , ... , , , , ...
Cached Biology News:COXEN model picks the best drug for ovarian cancer 2Quest for jellyfish robot leads to discovery of bending rules for animal wing, fin tips 2Healthy Lunchbox Challenge helps influence healthy eating habits in children 2Healthy Lunchbox Challenge helps influence healthy eating habits in children 3Healthy Lunchbox Challenge helps influence healthy eating habits in children 4
Shake 'n' Stack oven - New Model (includes 10 bottle capacity rotisserie, adjustable feet, drip tray, manual)...
... - Neurosphere is a system designed for ... neurospheres in a serum free environment. The kit ... which has been optimized for neural stem cell ... Genes & Development 10 :3129). Two growth ...
Request Info...
... RQ1 RNase-Free DNase is a ... single-stranded or double-stranded DNA to produce ... for use in applications where maintaining ... RQ1 DNase is qualified for use ...
Biology Products: